# Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)

> **NCT02622074** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 60 (actual)

## Conditions studied

- Triple Negative Breast Neoplasms

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Nab-paclitaxel
- **DRUG:** Anthracycline (doxorubicin)
- **DRUG:** Cyclophosphamide
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02622074
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-27
- **Primary completion:** 2018-05-31
- **Final completion:** 2019-11-18
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02622074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02622074, "Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02622074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*